Plain-English translation of NCT06015880 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of three medications — , , and — to see if they work together to treat aggressive B-cell lymphoma that has come back or stopped responding to earlier treatments. The study will first figure out the safest doses of these medications when given together, then watch how well the treatment works against the cancer.
Aggressive B-cell lymphoma that returns or doesn't respond to standard treatments is very difficult to manage, and patients need new options. This trial combines medications that work in different ways, hoping that together they will be more effective than any single treatment.
You likely qualify if…
You likely don't qualify if…
You will receive all three medications as part of repeated treatment cycles lasting 28 days each. is given as an intravenous infusion (through a vein) three times in the first cycle, then once per cycle. is given intravenously on the first day of each cycle, and is taken as an oral pill at home for 21 days of each cycle. You'll continue treatment for 8 to 17 cycles depending on how well your cancer responds, with regular blood tests and imaging scans to monitor your progress and any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States